Gene Therapy Breakthrough Restoring Hearing and Vision in Genetic Disorders

Usher syndrome and related genetic disorders that cause combined hearing and vision loss affect thousands of people worldwide. Akouos, Inc. has developed gene therapy methods targeting CLRN1 gene mutations, offering potential restoration of both hearing and vision in patients with these devastating genetic conditions.

The Problem

CLRN1-related disorders are rare genetic conditions characterized by progressive hearing loss and vision impairment, often manifesting as Usher syndrome or similar conditions. Mutations in the CLRN1 gene prevent proper production of the clarin-1 protein, which is critical for maintaining the function of sensory cells in both the inner ear (required for hearing) and the retina (required for vision). Patients with CLRN1 mutations experience progressive bilateral sensorineural hearing loss beginning in childhood or young adulthood, followed by progressive retinitis pigmentosa that gradually diminishes vision. This dual sensory loss profoundly impacts quality of life, affecting communication, mobility, and independence. Currently, no approved treatments address the underlying genetic cause, leaving patients reliant on hearing aids, cochlear implants, and low-vision aids that only partially compensate for sensory loss. The challenge in treating CLRN1 disorders is delivering functional copies of the CLRN1 gene to both the inner ear and the retina in a way that restores protein function while minimizing immune responses and side effects. The inner ear and retina are highly specialized tissues with unique delivery challenges.

What This Invention Does

Akouos has developed gene therapy methods that deliver functional CLRN1 gene sequences directly to affected sensory tissues. The approach uses engineered viral vectors – modified versions of naturally occurring viruses – that can penetrate the blood-retinal barrier and access inner ear tissues. These vectors carry the therapeutic CLRN1 gene in a form that cells can process to produce functional clarin-1 protein. The gene therapy method involves direct injection or systemic administration of the viral vector carrying CLRN1. Once the vector reaches target cells in the retina and inner ear, the gene is integrated into the cell’s genetic machinery, allowing those cells to produce clarin-1 protein. Restoration of clarin-1 protein function can help preserve or restore sensory cell function and prevent further deterioration. The approach is designed to be disease-modifying, potentially halting progression and even restoring function in affected sensory cells. By addressing the genetic root cause rather than just managing symptoms, the therapy represents a fundamentally different treatment paradigm for CLRN1-associated disorders, offering hope for restoration of both hearing and vision.

Key Features

CLRN1 Gene Delivery System. Engineered viral vectors specifically designed to deliver functional CLRN1 gene sequences to inner ear and retinal tissues.

Dual Sensory Tissue Targeting. The therapeutic approach addresses both hearing and vision loss by targeting sensory cells in both the inner ear and retina.

Cell-Based Gene Expression. Once delivered, the CLRN1 gene integrates into sensory cells, enabling production of clarin-1 protein for restored function.

Disease-Modifying Mechanism. Targets the genetic root cause of CLRN1 disorders rather than merely managing symptoms, potentially preventing progression.

Potential Vision and Hearing Restoration. May halt disease progression and potentially restore sensory function in affected tissues.

Who Is Behind It?

Akouos, Inc. is developing this innovation with inventors Emmanuel J. Simons and Robert Ng. The company is based in United States. This patent application is a divisional of an earlier filing, indicating ongoing development and refinement of the core technology over multiple patent generations.

Why It Matters

CLRN1-associated hearing and vision loss represents a significant unmet medical need affecting thousands of patients worldwide. Gene therapy for sensory disorders is an emerging field with tremendous commercial potential. If this therapy demonstrates efficacy in clinical trials, it could become a standard-of-care treatment commanding premium pricing for this indication and potentially opening pathways to address other genetic causes of hearing and vision loss.

Patent classifications focus on gene therapy (C12N 15/85), proteins and peptides (C07K 14/47), cellular therapies (C12N 5/079, A61K 35/30), and ophthalmological applications (A61P 27/16). This broad classification reflects the multi-disciplinary nature of gene therapy spanning molecular biology, biomedical engineering, and clinical medicine.

---

AU 2026201371 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.